No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Lotus Pharmaceutical Co., Ltd. operates as a pharmaceutical enterprise, specializing in the research, development, production, and sale of generic medicines. Its market presence extends across Taiwan, South Korea, the United States, and other global territories. The company primarily targets therapeutic areas such as oncology, cardiology, nephrology, women's health, anti-obesity, and central nervous system conditions with its generic product line. In addition to prescription generics, Lotus also offers a diverse array of over-the-counter drugs. Diversifying its business activities, the firm engages in the wholesale distribution of cosmetics, the retail of specialized clinical equipment, and provides biotechnology consulting. It also handles the sale of pharmaceuticals and medicinal chemicals, conducts marketing campaigns, offers market planning and business intelligence services, and provides advisory on health management and health technology. Furthermore, Lotus delivers a suite of services including project management for pharmaceutical regulatory compliance, data collection, and agency functions. It also operates as a healthcare consultancy and a Contract Research Organization (CRO). Established in 1966, Lotus Pharmaceutical Co., Ltd. maintains its principal office in Taipei City, Taiwan. The company is a subsidiary of Alvogen Emerging Markets Holdings Limited.
www.lotuspharm.com/zh-TWNo one on the platform currently holds 1795.TW.
No tracked institution reports a position in 1795.TW as of their last filing.
No one on the platform has traded 1795.TW yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 6.8% | 12.9% | — | — | — | |
| Rev. Growth % | 10.4% | 13.8% | ||||
| Profit Margin % | 23.0% | 21.2% | 12.2% | |||
| Free Cash Flow Margin % | 15.2% | 4.7% | 2.5% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $35.3B | +77.2% | $14.26 | $13.11–$15.42 | — | 2 |
| 2027 | $41.3B | +16.9% | $24.51 | $19.37–$29.37 | — | 4 |
| 2028 | $43.8B | +6.0% | $23.28 | $22.78–$23.80 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-13 | $3.42 | $2.42 | -29.2% |
| 2026-05-11 | $2.47 | $2.15 | -13.0% |
| 2026-03-13 | $5.26 | $4.26 | -19.0% |
| 2025-11-13 | $4.31 | $5.47 | +26.9% |
| 2025-08-11 | $5.28 | $2.77 | -47.5% |
| 2025-05-09 | $3.85 | $5.40 | +40.3% |
| 2025-03-06 | $3.30 | $4.27 | +29.4% |
| 2024-11-07 | $6.11 | $5.87 | -3.9% |
| $78.60 |
| +0.38% |
| $19.5B |
| — |
| 4114.TWOSynmosa Biopharma Corporation | $29.45 | +0.34% | $15.9B | — |
| 4119.TWSCI Pharmtech, Inc. | $59.80 | +0.34% | $7.1B | — |
Source: Financial Modeling Prep · peers by sector/industry